Trial Profile
Comparison of efficacy and safety of pazopanib and sunitinib in patients with metastatic renal cell carcinoma patients with poor-risk features
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 14 Jul 2017
Price :
$35
*
At a glance
- Drugs Pazopanib (Primary) ; Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- 14 Jul 2017 New trial record